Physician profile
Byron Cooper
NPI 1164484341
$5,369.33
in general payments reported to CMS, 2019-2025
39 companies · $840 in 2025
The $840 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,088 · 2020: $906 · 2021: $1,202 · 2022: $805 · 2024: $529 · 2025: $840.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,369.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,368.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $2,100.69 | 2019-2025 | Breztri, Airsupra, Tezspire |
| Glaxosmithkline, LLC. | $1,034.85 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Genzyme Corporation | $260.37 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $189.63 | 2020-2022 | |
| Jazz Pharmaceuticals INC. | $183.10 | 2021-2024 | |
| Verona Pharma, INC. | $139.87 | 2025 | Ohtuvayre |
| Itamar Medical INC | $130.76 | 2024 | Watchpatone |
| Takeda Pharmaceuticals U.S.A., INC. | $127.60 | 2019-2022 | |
| Amgen INC. | $127.55 | 2022-2025 | Tezspire, Krystexxa |
| Axsome Therapeutics, INC. | $119.70 | 2025 | Sunosi |
| Pfizer INC. | $116.39 | 2021-2024 | |
| Harmony Biosciences LLC | $76.77 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $66.18 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $64.60 | 2019-2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $58.26 | 2022 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optinose US, INC. | $54.87 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $43.47 | 2021-2024 | Gardasil, Gardasil 9, Capvaxive |
| Mallinckrodt Enterprises LLC | $42.03 | 2019 | |
| Abbvie INC. | $40.49 | 2019 | |
| Novo Nordisk INC | $39.24 | 2025 | Wegovy |
| Janssen Pharmaceuticals, INC | $30.05 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $28.32 | 2024 | Opsumit |
| Mallinckrodt Hospital Products INC. | $23.20 | 2020 | |
| Laborie Medical Technologies Corp. | $23.02 | 2025 | |
| Avadel Cns Pharmaceuticals, LLC | $21.89 | 2024 | Lumryz |
| Mylan Specialty L.P. | $21.31 | 2019 | |
| Astellas Pharma US INC | $21.02 | 2025 | Veozah |
| Lilly USA, LLC | $19.41 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $19.07 | 2021 | |
| Eisai INC. | $18.09 | 2020 | |
| Grifols USA, LLC | $17.73 | 2020 | |
| Csl Behring | $16.82 | 2019 | |
| Phathom Pharmaceuticals, INC. | $16.27 | 2024 | Voquezna |
| Capsovision, INC. | $15.68 | 2024 | Capsocam Plus |
| Amarin Pharma, INC. | $13.74 | 2019 | |
| Phadia US INC. | $12.38 | 2019 | |
| Philips North America LLC | $12.12 | 2022 | |
| Electromed, INC. | $11.74 | 2019 | |
| Bausch Health US, LLC | $11.05 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Byron Cooper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.